Given that MYCN transcriptionally activates MIR17HG in neuroblastoma (21) and medulloblastoma (22), we examined the expression levels of the miR-17–92 cluster across a panel of FP-RMS lines with variable expression of P3F and MYCN. This evidence concerns the gene MYCN and medulloblastoma.